CORC

在结果中检索

CORC

浏览/检索结果: 共230条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan
收藏  |  浏览/下载：58/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05
法治强化能够促进污染治理吗?——来自环保法庭设立的证据 期刊论文
经济研究, 2019, 期号: 2019年03期, 页码: 21-37
作者:  范子英;  赵仁杰
收藏  |  浏览/下载：7/0  |  提交时间：2019/09/18
Nitric oxide inhibits autophagy and promotes apoptosis in hepatocellular carcinoma. 期刊论文
Cancer science, 2019, 卷号: 110, 页码: 1054-1063
作者:  Zhang XiaoGang;  Jin Li;  Tian Zhen;  Wang Jing;  Yang Yuan
收藏  |  浏览/下载：29/0  |  提交时间：2019/11/19
apoptosis  NO  autophagy  NOS  HCC  
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：37/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：39/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 期刊论文
HEPATOLOGY, 2018, 卷号: 68
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载：21/0  |  提交时间：2019/12/05
On-Treatment ALT Normalization Has No Statistical Significant Impact on Liver Stiffness Regression in Chinese Chronic Hepatitis B Patients with Advanced Fibrosis or Cirrhosis Receiving Tenofovir Disoproxil Fumarate Therapy 期刊论文
HEPATOLOGY, 2018, 卷号: 68
作者:  Wei, Lai;  Shang, Jia;  Xie, Qing;  Jia, Zhansheng;  Gao, Pujun
收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace